Antibacterial and Anticancer Evaluation of Copper-Aluminum (CuAl) Layered Double Hydroxides (LDH) Synthesized Using Co-Precipitation Method Authors: Jiayan Shi, Yueran Wang, Mengting Xu, Shunjie Jin, Ying Yin, Kai He Khor, Xuan Zhou, Ali Bahadur, Kamyar Shameli, Sin-Yeang Teow Published: 2026 ABSTRACT PurposeThe advancement of nanotechnology has significantly accelerated the development of antibacterial and anticancer therapeutics for biomedical applications. Among emerging nanomaterials, layered double hydroxides (LDHs) offer several advantages, including ease of synthesis and inherent therapeutic properties. In this study, the antibacterial and anticancer activities of copper-aluminum (CuAl) LDHs were assessed.MethodsCuAl LDHs were synthesized via the co-precipitation method and characterized. Antibacterial activity was evaluated through broth microdilution, colony-forming unit (CFU) counts, followed by biofilm inhibition assays. Cytotoxicity experiments were conducted in monolayer and 3D tumor spheroid cultures, followed by mechanistic studies including reactive oxygen species (ROS), mitochondrial superoxide, apoptosis/necrosis, and cell cycle assays.ResultsThe particle sizes were 619.2 and 604.3 nm, with polydispersity index (PDI) values of 0.16 and 0.13 at pH 6 and 7.4, respectively. Zeta potential values ranged from +37.81 to +38.53 mV across pH 3 to 10, indicating good colloidal stability. The CuAl LDHs were effective against Gram-positive bacteria Streptococcus gallolyticus and Staphylococcus epidermidis, while showing lower activity against the Gram-negative bacteria Klebsiella aerogenes and Proteus vulgaris. Scanning electron microscopy (SEM) analysis showed that the LDHs resulted in envelope disruption, morphological deformation, and aggregation in all tested bacteria. In contrast, stronger antibiofilm activity was observed against Gram-negative bacteria. CuAl LDHs showed dose-dependent growth inhibition in both colorectal cancer (CRC) cell lines, HCT-116 and HT-29, particularly in 3D tumor spheroid models. Mechanistic studies revealed that CuAl LDH induced total ROS and mitochondrial superoxide production and triggered apoptosis in CRC cells, primarily through the downregulation of the anti-apoptotic genes BCL-2 and BCL2L1 (BCL-XL). While CuAl LDHs did not significantly alter cell cycle progression, a reduction in the expression of cell cycle-related genes, CCNE1 and CCNB1 was observed.ConclusionCuAl LDHs exhibit antibacterial, antibiofilm, and anticancer activities, indicating their potential as multifunctional materials for CRC-related biomedical applications. Their cytotoxic effects in CRC cells are associated with increased ROS generation, mitochondrial superoxide production, and apoptosis induction. Further studies are needed to assess their biocompatibility and selectivity toward normal cells, improve tumor-targeting capability, evaluate the implications of their relatively large particle size, and confirm the molecular mechanisms underlying their biological effects. Introduction Colorectal cancer (CRC) ranks as the third most common cancer and the third leading cause of cancer-related deaths globally in both men and women.1 Treatment options for CRC at different stages include surgery, chemotherapy, radiotherapy, targeted therapy, immunotherapy, and combination therapies. With advancements in precision medicine, the survival rate of CRC patients has improved over the years.2 However, the cost of treatment remains a significant challenge, particularly for patients in low-income countries.3 As a result, affordable chemotherapy remains a commonly used treatment for CRC. Unfortunately, many anticancer drugs, including 5-fluorouracil (5-FU), cisplatin, and irinotecan, often come with undesirable side effects. These limitations highlight the need for more effective, selective, and accessible therapeutic strategies. Nanomaterials have become a promising approach in anticancer treatment due to their unique properties, such as small size, high surface area, biocompatibility, and the ability to be functionalized for targeted drug delivery.4 Layered double hydroxides (LDHs) are newer 2D nanomaterials with exchangeable anions that can be loaded with anticancer drugs and functionalized with targeting agents, such as lectins, for selective delivery to cancer cells.5 LDHs have high biocompatibility, the ability to encapsulate a variety of drugs, and sustained release.6 The use of magnesium-aluminum (MgAl) LDH for anticancer applications has been extensively investigated as a drug deliver carrier and an anticancer nanomaterial.7 In contrast, copper–aluminum (CuAl) LDHs have received comparatively less attention, particularly in relation to CRC. CuAl LDHs are composed of positively charged layers made of Cu2+ and Al3+ ions, intercalated with various anions such as hydroxide or carbonate ions.8 This structure forms a type of hydrotalcite-like compound, which is known for its ability to exchange anions within the layers. This hydrotalcite-like structure permits anion exchange and may enable the incorporation of therapeutic molecules, thereby expanding the potential utility of CuAl LDHs as drug-delivery systems.9 For example, doxorubicin-loaded CuAl LDHs have demonstrated antitumor activity in MCF-7 breast cancer cells with limited toxicity in an in vivo model.8 In addition to their role as nanocarriers, CuAl LDHs may exhibit intrinsic biological activity because copper ions can participate in redox reactions and promote intracellular reactive oxygen species (ROS) generation.10 This property may contribute to anticancer effects. However, excessive copper release or ROS production may also induce oxidative damage in normal cells.11 Therefore, the cytotoxicity, copper-ion release behavior, cancer-cell selectivity, and biocompatibility of CuAl LDHs should be carefully evaluated before their translational potential can be established. CuAl LDHs have also demonstrated antibacterial activity. Kiani et al synthesized CuAl LDHs modified with Plantago ovata (PO), which effectively killed both Gram-positive Bacillus cereus and Gram-negative Pseudomonas aeruginosa.8 Similarly, Lv et al reported that CuAl LDHs exhibited strong antibacterial effects against Gram-positive Staphylococcus aureus and Gram-negative Escherichia coli and Klebsiella pneumoniae.12 Notably, when combined with a photothermal effect, their antibacterial efficacy was enhanced due to the increased release of copper ions and ROS production.12 In another study, Li et al also showed that CuAl LDHs were effective against E. coli and S. aureus, further supporting their broad-spectrum antibacterial potential.13 This property is particularly relevant to CRC because several bacterial species, including S. gallolyticus and K. aerogenes, have been associated with CRC development, progression, and CRC-related dysbiosis.14,15 However, the antibacterial and antibiofilm activities of CuAl LDHs against CRC-associated bacterial species remain insufficiently investigated. In the present study, CuAl LDHs were synthesized by co-precipitation and evaluated for their antibacterial, antibiofilm, and anticancer activities. Their antibacterial effects were assessed against selected Gram-positive and Gram-negative bacteria, including CRC-associated bacterial species. Their anticancer activity was evaluated in HCT-116 and HT-29 CRC cell lines using both monolayer and three-dimensional tumor spheroid models. Potential mechanisms underlying their cytotoxic effects were investigated through analyses of intracellular ROS generation, apoptosis/necrosis, cell-cycle distribution, and the expression of apoptosis- and cell-cycle-related genes. This study provides preliminary evidence of the multifunctional biological activity of CuAl LDHs rather than establishing their immediate clinical applicability. In particular, the relatively large particle size of the synthesized CuAl LDHs should be considered, as it may affect cellular uptake, tumor penetration, biodistribution, and suitability for systemic administration. Further studies are required to optimize particle size and surface properties, evaluate normal-cell toxicity and in vivo biocompatibility, and determine whether CuAl LDHs can achieve selective therapeutic effects in CRC. Materials and Methods Chemicals, Materials and Reagents Cu(NO3)2·3H2O (#13778-31-9), Na2CO3 (#24551-51-7), Al(NO3)3·9H2O (#25838-59-9), and NaOH (#12179-02-1) were purchased from Shanghai Macklin Biochemical Technology. The chemicals were used without any further purification. All chemicals and reagents were of analytical grade and dissolved in deionized (DI) water. Streptococcus gallolyticus (#188152), Staphylococcus epidermidis (#102555), Klebsiella aerogenes (#336764), and Proteus vulgaris (#337267) were purchased from Beina Culture Collection (BNCC), China. S. gallolyticus and S. epidermidis were cultured using brain heart infusion (BHI) broth (#LA0360, Solarbio) while K. aerogenes and P. vulgaris were cultured using Luria-Bertani (LB) broth (#L3022, Sigma). Dulbecco’s Modified Eagle’s Medium (DMEM) (#10566016), fetal bovine serum (FBS) (#A5670701), penicillin/streptomycin (#15140122), and phosphate-buffered saline (PBS) (#10010002) were obtained from Gibco, Thermo Fisher Scientific. McCoy’s 5A (modified) medium (#G4540) was purchased from Servicebio, Wuhan, China, while 0.25% trypsin-EDTA (#BL512A) was obtained from Biosharp Life Sciences. HCT-116 (#FH0027), HT-29 (#FH0024), NCM460 (#FH0541), and HaCaT (#FH0186) cell lines were purchased from Shanghai Fuheng Biotechnology Co. Ltd., Shanghai, China. HCT-116 was grown in McCoy’s 5A medium, while the other cell lines were maintained in DMEM. All media were supplemented with 10% FBS and 1% penicillin/streptomycin. Cells were maintained at 37°C, 5% CO2, and 95% humidity and harvested when they reached 70–80% confluence. Synthesis of CuAl LDHs The CuAl-LDHs were synthesized using the co-precipitation method at a constant pH as previously described.9 Briefly, 18 mmol of Cu(NO3)2·3H2O, 12 mmol of Na2CO3, and 6 mmol of Al(NO3)3-9H2O were dissolved in 100 mL of deionized (DI) water, and the solution was mixed well by magnetic stirring at 500 rpm at room temperature. NaOH solution was then added dropwise and the pH of the solution was controlled at 10. The reaction mixture was incubated at 30°C for 24 h. After the incubation, the solution was centrifuged at 5000 rpm for 3 min to collect the precipitate, washed three times with DI water and ethanol to remove impurities, and finally dried in an oven at 60°C for 12 h to obtain CuAl LDH with an atomic ratio of copper to aluminum of 3:1. Characterization of CuAl LDH The vibrational modes of the active components were assessed by Fourier transform-infrared (FTIR) spectroscopy (Shimadzu IRAffinity-1S, Japan) by preparing the samples in potassium bromide (KBr) at a resolution limit of 2 cm−1 over the wavelength range of 4000–400 cm−1, and the data were analyzed using the Bruker Opus 7.2 spectroscopy software. The crystalline nature of CuAl LDHs was studied using an X-ray diffraction (XRD) instrument (Rigaku Rint2000 vertical goniometer, Japan) at 40 kV and 150 mA. A 1 mg/mL CuAl LDH suspension was dispersed in pH-adjusted deionized water with 10 mM NaCl by ultrasonication for 10 min, and the hydrodynamic particle size, PDI, and zeta potential were measured using dynamic light scattering (DLS) on a Zetasizer Lab (Malvern Panalytical, UK) at 25°C. The structure of CuAl LDHs was evaluated using a Zeiss scanning electron microscope (SEM) at 3 kV equipped with energy-dispersive X-ray spectroscopy (EDS) for element mapping analysis. Determination of Minimum Inhibitory Concentration Antibacterial assays were performed according to the Clinical and Laboratory Standards Institute (CLSI) guidelines using the broth microdilution method with some modifications. Gram-positive bacteria (S. epidermidis and S. gallolyticus) were inoculated into BHI while Gram-negative bacteria (K. aerogenes and P. vulgaris) were inoculated into LB, and incubated at 37°C overnight at 250 rpm using a rotary shaker. These cultures were adjusted to a 0.5 McFarland standard, equivalent to ~108 colony-forming units per milliliter (CFU/mL) using sterile BHI or LB. 2-fold serially diluted CuAl LDH at concentrations of 0, 15.62, 31.25, 62.53, 125, 250, 500, and 1000 μg/mL (100 μL/well) were added to a 96-well plate using BHI or LB as diluents. Then, 100 μL of OD-adjusted bacteria resulting in 5×105 CFU/mL was added to the 96-well plate followed by 24 h of incubation. The plate was mixed on a microplate shaker for 2 min and read using a microplate reader (Tecan Infinite M200, Germany) at OD600. Each well was prepared in triplicate, the concentration-response graph was plotted, and the percentage of bacterial growth was calculated using the formula below: \documentclass[12pt]{minimal} \usepackage{wasysym} \usepackage[substack]{amsmath} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage[mathscr]{eucal} \usepackage{mathrsfs} \DeclareFontFamily{T1}{linotext}{} \DeclareFontShape{T1}{linotext}{m}{n} {linotext }{} \DeclareSymbolFont{linotext}{T1}{linotext}{m}{n} \DeclareSymbolFontAlphabet{\mathLINOTEXT}{linotext} \begin{document}$$\mathrm{\eqalign{& Bacterial\,{\mathrm{ }}growth{\mathrm{ }}\,\left(\% \right){\mathrm{ }} = {\mathrm{ }}\left({mean\,{\mathrm{ }}of\,{\mathrm{ }}O{D_{treated\,{\mathrm{ }}sample}} - {\mathrm{ }}mean\,{\mathrm{ }}of\,{\mathrm{ }}O{D_{back\,ground\,{\mathrm{ }}of\,{\mathrm{ }}LDHs}}} \right)/{\mathrm{ }} \cr & \,\,\,\,\,\,\,\,\,\,\,\,\,\,\,\,\,\left({mean\,{\mathrm{ }}of\,{\mathrm{ }}O{D_{untreated\,{\mathrm{ }}sample}} - {\mathrm{ }}mean\,{\mathrm{ }}of\,{\mathrm{ }}O{D_{back\,ground{\mathrm{ }}\,of{\mathrm{ }}\,broth}}} \right){\mathrm{ }} \times {\mathrm{ }}100 \cr}}$$\end{document} The minimum inhibitory concentration causing 50% growth inhibition (MIC50) was determined using an online calculator tool (https://www.aatbio.com/tools/ic50-calculator). Antibiofilm Assay LDHs-treated bacteria were prepared in a 96-well plate as described above. After 24 h, planktonic cells and the medium were discarded. The adherent biofilm was rinsed with water twice and air-dried for 30 min. Cells were stained using 200 μL of 0.4% crystal violet for 30 min. Then, the crystal violet was discarded. The stained cells were rinsed with water five times to remove any remaining crystal violet and air-dried for 30 min. Then, 100 μL of absolute ethanol was added and the plate was mixed on a microplate shaker for 2 min to dissolve the stained cells. Subsequently, the ethanol was transferred into a new 96-well plate and the absorbance was measured with a microplate reader at OD570. The percentage of biofilm formation was calculated using the formula below: \documentclass[12pt]{minimal} \usepackage{wasysym} \usepackage[substack]{amsmath} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage[mathscr]{eucal} \usepackage{mathrsfs} \DeclareFontFamily{T1}{linotext}{} \DeclareFontShape{T1}{linotext}{m}{n} {linotext }{} \DeclareSymbolFont{linotext}{T1}{linotext}{m}{n} \DeclareSymbolFontAlphabet{\mathLINOTEXT}{linotext} \begin{document}$$\mathrm{Biofilm\,{\mathrm{ }}formation\,{\mathrm{ }}\left(\% \right){\mathrm{ }} = {\mathrm{ }}mean\,{\mathrm{ }}of\,{\mathrm{ }}O{D_{treated\,{\mathrm{ }}sample}}/{\mathrm{ }}mean\,{\mathrm{ }}of\,{\mathrm{ }}O{D_{untreated\,{\mathrm{ }}sample}} \times {\mathrm{ }}100}$$\end{document} Colony Formation Assay Bacteria treated with 0.25, 0.5 and 1 mg/mL LDHs and controls were prepared in 96-well plates as described above. The bacteria were diluted using PBS to 10−4, 10−5, and 10−6 and 10 μL of the diluted bacterial suspension from each triplicate well were plated onto BHI or LB agar plates. The next day, images of the agar plates were captured using a ChemiDoc MP Imaging System (Bio-Rad Laboratories) and the colony numbers were enumerated to determine the CFU/mL. The CFU count versus concentration graph was plotted. Time-Kill Curve Time–kill curve assays were conducted to confirm the antibacterial activity of the CuAl LDHs at different time points (0, 4, 12 and 24 h). Bacterial suspensions and LDH treatments (0.25, 0.5 and 1 mg/mL) were prepared as mentioned above. At each time point, serial dilutions were performed and 10 μL of the diluted bacterial suspension from each triplicate well was plated onto BHI or LB agar plates. The next day, images of the agar plates were captured using a ChemiDoc MP Imaging System (Bio-Rad Laboratories) and the colony numbers were enumerated to determine the CFU/mL. The CFU count versus time of treatment was plotted. Scanning Electron Microscopy (SEM) Analysis LDH-treated bacteria were prepared in a 96-well plate as described above. Briefly, the bacteria were treated with 1000 μg/mL LDHs for 24 h, harvested by centrifugation, and washed twice with PBS. The bacterial pellets were fixed with 2.5% glutaraldehyde at 4°C overnight, followed by washing with phosphate buffer and post-fixation in 1% osmium tetroxide for 1 h at room temperature. After fixation, bacteria were washed with phosphate buffer and dehydrated through a graded ethanol series (30%, 50%, 70%, 80%, 90%, 95%, 100%, 100%). The dehydrated samples were subsequently immersed in a 1:1 (v/v) ethanol/isoamyl acetate solution for 30 min and then incubated in 100% isoamyl acetate for 1 h. Following critical point drying, the samples were mounted onto aluminum stubs and sputter-coated with a thin layer of gold prior to observation. The bacterial morphology and surface characteristics were examined and images were acquired using a scanning electron microscope (SEM) (ZEISS Sigma 360, Germany) at 20,000× and 50,000× magnification at an accelerating voltage of 3 kV. Cytotoxicity Assay in Monolayer Model The cytotoxic effect of CuAl LDH was assessed using the CellTiter-Glo luminescent cell viability assay (#G9241, Promega) as previously described.16,17 Briefly, 5 × 103 cells per well (100 μL/well) were seeded onto a white 96-well plate and incubated overnight at 37°C in a 5% CO2, 95% humidified incubator. The next day, 2-fold serially diluted CuAl LDH at concentrations of 0, 15.62, 31.25, 62.53, 125, 250, 500, and 1000 μg/mL (100 μL/well) was added to the wells, followed by 24 h of incubation. Then, 20 μL of cell viability reagent per well was added, and the plate was incubated at room temperature in the dark for 1 h. The plate was read using a microplate reader (Tecan). The concentration-response graph was plotted, and the percentage of cell viability was calculated using the formula below: \documentclass[12pt]{minimal} \usepackage{wasysym} \usepackage[substack]{amsmath} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage[mathscr]{eucal} \usepackage{mathrsfs} \DeclareFontFamily{T1}{linotext}{} \DeclareFontShape{T1}{linotext}{m}{n} {linotext }{} \DeclareSymbolFont{linotext}{T1}{linotext}{m}{n} \DeclareSymbolFontAlphabet{\mathLINOTEXT}{linotext} \begin{document}$$\mathrm{\eqalign{& Cell{\mathrm{ }}viability\,{\mathrm{ }}\left(\% \right){\mathrm{ }} = {\mathrm{ }}mean\,{\mathrm{ }}relative\,{\mathrm{ }}luminescence\,{\mathrm{ }}unit{\mathrm{ }}{\left({RLU} \right)_{treated\,{\mathrm{ }}sample}}/{\mathrm{ }} \cr & \,\,\,\,\,\,\,\,\,\,\,\,\,\,\,\,\,\,\,\,\,\,\,\,\,\,\,\,\,\,\,\,\,\,\,\,\,\,\,\,mean\,{\mathrm{ }}RL{U_{untreated\,{\mathrm{ }}sample}} \times {\mathrm{ }}100 \cr}}$$\end{document} Inhibitory concentration causing 50% growth inhibition (IC50) was determined using an online calculator tool (https://www.aatbio.com/tools/ic50-calculator). For imaging purposes, cells were prepared and treated with CuAl LDH as described above. After 24 h of incubation, cells were washed three times with PBS and fixed using 10% formalin for 10 min followed by PBS washing three times. A 1 µg/mL DAPI solution (#62248, Thermo Scientific) was added into each well, incubated for 10 min, followed by PBS washing. The cells were visualized under an automated fluorescence microscope (BZ-X800, Keyence, USA), and images were captured at 200x magnification. Inductively Coupled Plasma Mass Spectrometry (ICP-MS) Cellular uptake experiments were performed through ICP-MS. Briefly, cells were seeded into T75 flasks and allowed to attach overnight until approximately 80% confluence was reached. The cells were then treated with CuAl LDH at their respective IC50 concentrations for 24 h. Untreated cells served as the control group. After treatment, the culture medium was discarded and the cells were washed five times with ice-cold PBS to remove extracellular LDHs. After detachment using trypsin–EDTA, the cells were pelleted by centrifugation and washed with PBS an additional three times. The cell counts were determined and the harvested cell pellets were weighed before being digested in a mixture containing concentrated nitric acid (HNO3) and 30% H2O2 in a 3:1 (v/v) ratio. Cell pellets were dispersed by sonication for 5 min and incubated at 80°C overnight until complete digestion was achieved. After cooling to room temperature, the digested samples were diluted to 10 mL with 2% HNO3. Intracellular Cu and Al content was quantified using a NexION 1000G ICP-MS (PerkinElmer, USA) according to the manufacturer’s instructions. Standard Cu and Al solutions were prepared to generate a calibration curve prior to analysis. The intracellular uptake of CuAl and CuAl-5FU LDHs was expressed as Cu and Al concentrations (in ng) normalized to the total cell number (per million cells). Cytotoxicity Assay in Tumor Spheroid Model To assess the tissue-penetrating capacity of CuAl LDHs, we performed the cytotoxicity assay on the 3D tumor spheroid model as previously described by our group.18,19 Briefly, 5×103 cells were seeded into a CellCarrier Spheroid ultra-low attachment 96-well microplate (#6055330, Perkin Elmer) and incubated for 48 h to allow spheroid formation. Subsequently, spheroids were treated with CuAl LDHs at the concentrations, as described above. After 24 h of treatment, 20 μL of 3D CellTiter-Glo reagent (#G9681. Promega) was added to each well and incubated at room temperature in the dark for 1 h. Luminescence was then measured, data were analyzed, and IC50 values were calculated as described above. Live/dead staining was conducted as previously described.16 CRC spheroids were stained with 0.5 μM Calcein AM (#C1430, Invitrogen) and 16 μg/mL propidium iodide (PI, #P1304MP, Invitrogen) for 1 h at 37°C. After staining, spheroids were visualized under an automated fluorescence microscope (BZ-X800, Keyence, USA), and images were captured at 200x magnification. Reactive Oxygen Species (ROS) Assay ROS levels in CRC cells were assessed using the ROS Detection Kit (#SH0403, BT LAB). A total of 2×104 cells per well were seeded onto a 48-well microplate and incubated for 24 h. After treatment with CuAl LDH as described above, cells were washed three times with PBS and incubated with 100 μL of 10 μM 2′, 7′-dichlorodihydrofluorescein diacetate (DCFH-DA) for 30 min at 37°C in a 5% CO2 incubator. Following incubation, the cells were washed an additional three times with PBS and observed under an automated fluorescence imaging system (Keyence BZ-X810, Japan). Images were captured at 200x magnification. Fluorescence intensity was quantified using ImageJ software (NIH), and relative fluorescence units (RFU) was calculated as the ratio of fluorescence intensity to cell number. The increase in ROS production was expressed relative to the untreated control group using the formula below: \documentclass[12pt]{minimal} \usepackage{wasysym} \usepackage[substack]{amsmath} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage[mathscr]{eucal} \usepackage{mathrsfs} \DeclareFontFamily{T1}{linotext}{} \DeclareFontShape{T1}{linotext}{m}{n} {linotext }{} \DeclareSymbolFont{linotext}{T1}{linotext}{m}{n} \DeclareSymbolFontAlphabet{\mathLINOTEXT}{linotext} \begin{document}$${\mathrm{Relative\,fluorescence\,intensity= Fluorescence\,intensity\,/\,Number\,of\,cells}}$$\end{document} Mitochondrial Superoxide Assay A Mitochondrial Superoxide Assay Kit (#S0062S, Beyotime) containing MitoNeoD and mSoxUp was used for mitochondrial superoxide detection. CRC cells were seeded and treated as previously described in the ROS assay. For the positive control group, cells were treated with 1× mSoxUp 4 h prior to staining. After treatment, the cells were washed with PBS and incubated with 5 μM MitoNeoD and 5 μM Hoechst 33342 (#HY15559, MedChemExpress) for 30 min at 37°C in a 5% CO2 incubator. Cells were washed with PBS and then observed under an automated fluorescence imaging system (Keyence BZ-X810, Japan). Images were captured at 200× magnification. Relative fluorescence intensity was quantified as previously described in the ROS assay. Apoptosis Assay Apoptotic activity in CRC cells was assessed using an Annexin V-FITC/PI Apoptosis Detection Kit (#C1062L, Beyotime). Briefly, 1.5×105 cells per well were seeded in a 6-well plate and incubated overnight. The next day, cells were treated with CuAl LDH at their respective IC50 concentrations as described above. After treatment, the cells were washed with PBS, harvested, and resuspended in binding buffer. Annexin V-FITC and propidium iodide (PI) were added according to the manufacturer’s instructions. The stained cells were filtered through a 40 μm cell strainer and analyzed using a flow cytometer (NovoCyte 3005, Agilent, USA). A total of 10,000 events were collected per sample, and the data were analyzed using NovoExpress software (Agilent, USA). Cell Cycle Analysis Cells were seeded, treated, and harvested as described above. Following treatment, the cells were washed with PBS and fixed in 70% ethanol at 4°C for 1 h. After fixation, cells were stained with PI/RNase staining solution (#F10797, Invitrogen) for 30 min at room temperature in the dark. The stained cells were then passed through a 40 μm cell strainer and analyzed using a flow cytometer. Cell cycle distribution was determined using the automated cell cycle analysis protocol provided in the NovoCyte instrument manual. DNA content was assessed by PI fluorescence, and the proportion of cells in each phase of the cell cycle (G1, S, and G2/M) was quantified using NovoExpress software. Gene Expression Analysis Levels of gene expression were assessed using quantitative PCR (qPCR). Following treatment with the IC50 concentration of CuAl LDH, total RNA was isolated from 8×105 HCT-116 and HT-29 cells using a commercial RNA extraction kit (#4992858, Tiangen, China), following the manufacturer’s instructions. The concentration and quality of RNA were determined using a NanoDrop UV spectrophotometer (Thermo Scientific, USA). Using a SYBR Green One-Step qRT-PCR kit (#D7268M, Beyotime, China), 100 ng of RNA was reverse transcribed into complementary DNA (cDNA) and mixed with gene-specific primers for BCL-2, BCL2L1, BAX, CASP3, CCNE1, CCNB1, and CDK1 (Sino Biological, USA). Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (Sino Biological, USA) was used as a housekeeping gene. qPCR was performed on a real-time thermal cycler (Roche LightCycler 96, Roche Diagnostics, Germany) for 45 cycles. The gene expression levels were measured using the 2−ΔΔCt method. Statistical Analysis Statistical analyses were performed using SPSS software (Chicago, USA) version 27. Data are presented as the mean ± standard deviation (SD) from three independent experiments. Differences among more than two experimental groups were analyzed using one-way analysis of variance (ANOVA), followed by Tukey’s post hoc multiple-comparison test. A value of p < 0.05 was considered statistically significant. The significance level was indicated in the respective graphs. Results Characterization of CuAl LDH Figure 1A shows the FTIR spectra of the CuAl LDH. The peaks at around 3442 cm−1 and 1633 cm−1 were attributed to OH-stretching and bending modes of the interlayer water and hydroxyls, respectively.20 The peak observed at 1362 cm−1 was related to the vibration mode of CO32– anions in CuAl-LDH interlayers.21 The vibration mode of the carbonate anions was also illustrated at the 863 cm−1 absorption peak.20 The peaks at lower wavenumbers 595 cm−1 and 450 cm−1 corresponded to the stretching vibrations of the M−O−H and M-O bonds, respectively.22 Figure 1Characterization of CuAl LDHs. (A) Fourier transform-infrared spectroscopy (FTIR); (B) X-ray diffraction (XRD) analysis; (C) Hydrodynamic diameter and zeta (ζ) potential analysis at different pH; (D) Scanning electron microscopy (SEM), scale bars represent 500, 200, and 100 nm at magnifications of 50kx, 100kx, and 200kx, respectively; (E) Energy dispersive X-ray spectroscopy (EDS).Image A: Line graph of absorbance vs wavenumber (cm superscript -1) from 500 to 4000. Peaks at 450, 595, 863, 1362, 1633 and 3442 cm superscript -1. Image B: Line graph of intensity vs 2 theta (degrees) from 0 to 70. Reflections: CuAl, 003, 006, 101, 012, 200, 015, 018, 110, 113. Image C: Two plots. Left: Intensity (%) vs hydrodynamic diameter (nm) on a log scale (100-10000 nm) for pH 6.0 and 7.4, peaking at 800-1000 nm. Z average (nm) and polydispersity index: pH 6.0: 619.2 plus or minus 15.2, 0.16 plus or minus 0.03; pH 7.4: 604.3 plus or minus 44.7, 0.13 plus or minus 0.10. Right: Zeta potential (mV) vs pH (3-11), with points at 36.70 (pH 6), 38.28 (pH 8), 12.84 (pH 11). Image D: SEM micrographs at 50,000x, 100,000x, 200,000x, with scale bars of 500 nm, 200 nm, 100 nm. Image E: EDX spectrum with energy (keV) vs counts/keV. Elemental composition: Cu 49.45 wt%, O 26.20 wt%, C 16.99 wt%, Al 6.82 wt%, N 0.54 wt%; Atomic %: Cu 18.88, O 39.73, C 34.32, Al 6.13, N 0.94; Total 100%.Five-panel plots of CuAl LDH characterization showing peaks, size distributions, zeta trend and micrographs. Characterization of CuAl LDHs. (A) Fourier transform-infrared spectroscopy (FTIR); (B) X-ray diffraction (XRD) analysis; (C) Hydrodynamic diameter and zeta (ζ) potential analysis at different pH; (D) Scanning electron microscopy (SEM), scale bars represent 500, 200, and 100 nm at magnifications of 50kx, 100kx, and 200kx, respectively; (E) Energy dispersive X-ray spectroscopy (EDS). In the XRD pattern (Figure 1B), the diffraction peaks with 2θ angles of 11.7, 23.6, 32.8, 35.7, 38.7, 40.4, 48.8, 58.8, and 60.8 corresponded to (003), (006), (101), (012), (200), (015), (018), (110), and (113) reflections, respectively, for CuAl-LDHs based on the JCPDS No. 00–046-0099 and 01–085-7183 standard cards.9 The peaks at 11.73° correspond to carbonate (CO32−) intercalated in the LDH which results from Na2CO3.22 DLS analysis showed that the synthesized CuAl LDHs had a mean hydrodynamic diameter of 619.2 nm at pH 6.0 and decreased slightly to 604.3 nm at neutral pH 7.4 (Figure 1C). The polydispersity index (PDI) values at pH 6.0 and pH 7.4 were 0.16 and 0.13, respectively, indicating a narrow particle size distribution, a homogeneous population, and minimal aggregation. The zeta potential of CuAl LDH remained stable, ranging from +38.53 to +37.81 mV between pH 3 and pH 10, indicating good colloidal stability. However, it dropped sharply to +12.84 mV at pH 11, which was supported by visible aggregation in the suspension, suggesting loss of surface charge repulsion at high alkalinity (Figure 1C). The morphology and size of CuAl LDHs were characterized by SEM (Figure 1D). At low magnification (50kx), homogeneous nanoparticles were visible in the SEM image. At high magnification (200kx), two-dimensional sheet-like morphology was observed, which was consistent with the previous work.9 EDS was used to evaluate the chemical composition of CuAl LDHs confirming the presence of copper (Cu), oxygen (O), carbon (C), aluminum (Al), and nitrogen (N) elements with 49.45, 26.2, 16.99, 6.82 and 0.54 wt%, respectively (Figure 1E). Antibacterial and Antibiofilm Activities of CuAl LDH A broth microdilution assay was performed to determine the MIC values of CuAl LDH against two Gram-positive (S. gallolyticus and S. epidermidis) and two Gram-negative (K. aerogenes and P. vulgaris) bacteria. Concentration-dependent bacterial growth inhibition of CuAl LDH was seen in both Gram-positive and Gram-negative bacteria with more pronounced bacterial growth inhibitory activity toward Gram-positive bacteria, particularly in S. epidermidis in which up to 86% of bacteria were killed at 1 mg/mL (Figure 2A). For Gram-negative bacteria, a maximum of 48% and 43% inhibition was seen at in K. aerogenes and P. vulgaris, respectively following 1 mg/mL treatment. Since the MIC values of all bacteria were higher than the highest test concentration of 1 mg/mL, we evaluated the MIC50 values instead. As shown in Table 1, the lowest MIC50 value of CuAl LDH was observed in S. epidermidis (626.89 μg/mL), followed by another Gram-positive strain, S. gallolyticus (725.41 μg/mL). Interestingly, in contrast to the antibacterial activity, more pronounced biofilm inhibition was observed in Gram-negative bacteria compared with Gram-positive bacteria (Figure 2B). At 1 mg/mL CuAl LDH treatment, K. aerogenes and P. vulgaris showed up to ~62% biofilm inhibition, whereas S. gallolyticus and S. epidermidis exhibited less than 20% inhibition.Table 1MIC50 Values of CuAl LDH Against Tested Bacterial StrainsGram-positive bacteria (µg/mL)Gram-negative bacteria (µg/mL)Strep. gallolyticusStaph. epidermidisKleb. aerogenesProteus vulgarisMIC50725.41 ± 41.7626.89 ± 72.8>1000>1000 Figure 2Antibacterial (upper panel) and antibiofilm (lower panel) activities of CuAl-LDHs (0–1000 μg/mL) in (A) gram-positive and; (B) gram-negative bacteria. Error bars represent SD. ns – not significant, *p < 0.05, **p < 0.01, ***p < 0.001.The image A showing two grouped bar charts for Gram-positive bacteria. Top chart y-axis label, Bacterial growth percent, range 0 to 120. x-axis categories, S. gallolyticus and S. epidermidis. Legend concentrations, 0, 15.6, 31.3, 62.5, 125, 250, 500, 1000 microgram per milliliter. S. gallolyticus bars are about 100, 100, 108, 105, 100, 85, 80, 25. S. epidermidis bars are about 100, 90, 85, 82, 78, 72, 68, 15. Text above groups includes ns and asterisk. Bottom chart y-axis label, Biofilm growth percent, range 0 to 120. Same x-axis categories and concentration legend. S. gallolyticus bars are about 100, 90, 82, 88, 85, 84, 80, 80. S. epidermidis bars are about 100, 95, 98, 95, 97, 98, 92, 88. Text above groups includes ns and asterisks. The image B showing two grouped bar charts for Gram-negative bacteria. Top chart y-axis label, Bacterial growth percent, range 0 to 120. x-axis categories, K. aerogenes and P. vulgaris. Same concentration legend. K. aerogenes bars are about 100, 95, 97, 96, 88, 78, 75, 52. P. vulgaris bars are about 100, 98, 100, 82, 88, 70, 50, 55. Text above groups includes ns and asterisk. Bottom chart y-axis label, Biofilm growth percent, range 0 to 120. Same x-axis categories and concentration legend. K. aerogenes bars are about 100, 85, 75, 78, 72, 68, 58, 38. P. vulgaris bars are about 100, 52, 45, 46, 40, 35, 30, 36. Text above groups includes asterisk and asterisk.A grouped bar chart showing bacterial and biofilm growth across CuAl LDH concentrations in four bacteria. Table 1MIC50 Values of CuAl LDH Against Tested Bacterial StrainsGram-positive bacteria (µg/mL)Gram-negative bacteria (µg/mL)Strep. gallolyticusStaph. epidermidisKleb. aerogenesProteus vulgarisMIC50725.41 ± 41.7626.89 ± 72.8>1000>1000 MIC50 Values of CuAl LDH Against Tested Bacterial Strains Antibacterial (upper panel) and antibiofilm (lower panel) activities of CuAl-LDHs (0–1000 μg/mL) in (A) gram-positive and; (B) gram-negative bacteria. Error bars represent SD. ns – not significant, *p < 0.05, **p < 0.01, ***p < 0.001. To further assess its antibacterial activity, we conducted colony-forming unit (CFU) assays on CuAl-treated bacteria at concentrations of 0, 250, 500, and 1000 μg/mL. A clear concentration-dependent reduction in CFU counts were observed compared to untreated controls (Figure 3). Time-kill assays further confirmed the bacteriostatic nature of CuAl. Notably, although Gram-negative bacteria were less sensitive overall, their growth remained limited even after 24 h of treatment at 1 mg/mL (Figure 3C and D). In contrast, both Gram-positive strains showed markedly suppressed growth under the same conditions (Figure 3A and B). Figure 3Colony count (left panel) of bacteria treated with CuAl-LDHs and their corresponding time-kill curves (right panel). (A) Streptococcus gallolyticus; (B) Staphylococcus epidermidis; (C) Klebsiella aerogenes and; (D) Proteus vulgaris. Error bars represent SD. *p < 0.05, **p < 0.01, ***p < 0.001.Image A showing CFU count bar graph and time-kill curve for S. gallolyticus. Bar graph x-axis label: Concentration (microgram per milliliter). Bar graph y-axis label: Colony forming unit (times 10 superscript 6 CFU per milliliter). Bars: 0 equals 90; 250 equals 55 with double asterisk; 500 equals 30 with triple asterisk; 1000 equals 15 with triple asterisk. Error bars shown. Line graph x-axis label: Time (hr). Line graph y-axis label: CFU count (times 10 superscript 6 CFU per milliliter). Series labeled 0, 250, 500, 1000. Values: at 0 hr, all approximately 0; at 4 hr, 0 equals 5, 250 equals 5, 500 equals 3, 1000 equals 0; at 12 hr, 0 equals 55, 250 equals 45, 500 equals 40, 1000 equals 5; at 24 hr, 0 equals 165, 250 equals 135, 500 equals 105, 1000 equals 10. Markers and connecting lines distinguish series; error bars shown. Image B showing CFU count bar graph and time-kill curve for S. epidermidis. Bar graph x-axis label: Concentration (microgram per milliliter). Bar graph y-axis label: Colony forming unit (times 10 superscript 7 CFU per milliliter). Bars: 0 equals 70; 250 equals 22 with single asterisk; 500 equals 8 with double asterisk; 1000 equals 0 with double asterisk. Error bars shown. Line graph x-axis label: Time (hr). Line graph y-axis label: CFU count (times 10 superscript 8 CFU per milliliter). Series labeled 0, 250, 500, 1000. Values: at 0 hr and 4 hr, all approximately 0; at 12 hr, 0 equals 15, 250 equals 18, 500 equals 10, 1000 equals 0; at 24 hr, 0 equals 100, 250 equals 65, 500 equals 40, 1000 equals 0. Markers and connecting lines distinguish series; error bars shown. Image C showing CFU count bar graph and time-kill curve for K. aerogenes. Bar graph x-axis label: Concentration (microgram per milliliter). Bar graph y-axis label: Colony forming unit (times 10 superscript 7 CFU per milliliter). Bars: 0 equals 270; 250 equals 55 with triple asterisk; 500 equals 40 with triple asterisk; 1000 equals 20 with triple asterisk. Error bars shown. Line graph x-axis label: Time (hr). Line graph y-axis label: CFU count (times 10 superscript 7 CFU per milliliter). Series labeled 0, 250, 500, 1000. Values: at 0 hr, all approximately 0; at 4 hr, 0 equals 10, 250 equals 10, 500 equals 8, 1000 equals 5; at 12 hr, 0 equals 80, 250 equals 50, 500 equals 40, 1000 equals 30; at 24 hr, 0 equals 330, 250 equals 60, 500 equals 70, 1000 equals 45. Markers and connecting lines distinguish series; error bars shown. Image D showing CFU count bar graph and time-kill curve for P. vulgaris. Bar graph x-axis label: Concentration (microgram per milliliter). Bar graph y-axis label: Colony forming unit (times 10 superscript 7 CFU per milliliter). Bars: 0 equals 80; 250 equals 50 with double asterisk; 500 equals 40 with double asterisk; 1000 equals 32 with double asterisk. Error bars shown. Line graph x-axis label: Time (hr). Line graph y-axis label: CFU count (times 10 superscript 7 CFU per milliliter). Series labeled 0, 250, 500, 1000. Values: at 0 hr, all approximately 0; at 4 hr, 0 equals 5, 250 equals 5, 500 equals 5, 1000 equals 5; at 12 hr, 0 equals 35, 250 equals 35, 500 equals 30, 1000 equals 30; at 24 hr, 0 equals 170, 250 equals 40, 500 equals 85, 1000 equals 45. Markers and connecting lines distinguish series; error bars shown. Across A to D, bar graphs show lower colony forming unit values at higher concentration and line graphs show higher CFU count at 24 hr for series labeled 0 compared with series labeled 1000.A composite of 4 bar graphs and 4 line graphs of CFU counts and time-kill curves by concentration. Colony count (left panel) of bacteria treated with CuAl-LDHs and their corresponding time-kill curves (right panel). (A) Streptococcus gallolyticus; (B) Staphylococcus epidermidis; (C) Klebsiella aerogenes and; (D) Proteus vulgaris. Error bars represent SD. *p < 0.05, **p < 0.01, ***p < 0.001. The SEM analysis revealed substantial morphological alterations in bacterial cells following LDH treatment. As shown in Figure 4A, untreated coccoid bacteria S. gallolyticus and S. epidermidis exhibited a regular spherical morphology with smooth and intact cell surfaces and formed characteristic grape-like clusters. The cell envelopes appeared well-defined with no visible signs of structural damage. In contrast, LDH-treated coccoid bacteria displayed pronounced surface irregularities, including roughened cell walls, deformation of the spherical shape, membrane shrinkage, and the presence of particulate deposits on the cell surface. At higher magnification, some cells exhibited collapsed or wrinkled morphologies, suggesting disruption of cell envelope integrity. Similarly, untreated rod-shaped bacteria K. aerogenes and P. vulgaris maintained their smooth and intact bacillary structures (Figure 4B). Following LDH exposure, marked morphological damage was observed, characterized by surface roughening, distortion of the rod shape, and the appearance of amorphous aggregates associated with bacterial cells. Some cells showed evidence of shrinkage and surface collapse, while extensive particle accumulation was observed around and on the bacterial surfaces. The degree of aggregation appeared to increase after treatment, with bacterial cells embedded within dense particulate clusters. These observations indicate that LDH treatment induces significant structural damage to both Gram-positive coccoid and Gram-negative rod-shaped bacteria, leading to cell envelope disruption, morphological deformation, and bacterial aggregation. The presence of particulate deposits on bacterial surfaces further suggests strong interactions between LDH nanoparticles and bacterial cell envelopes, which may contribute to the antibacterial activity of the material. Figure 4Representative SEM images of (A) coccoid (upper panel) and (B) rod-shaped (lower panel) bacteria following LDH treatment. Untreated bacteria exhibited intact morphology with smooth cell surfaces, whereas LDH-treated bacteria showed surface roughening, deformation, shrinkage, and aggregation. High-magnification images (bottom row of each panel) highlight structural damage and nanoparticle deposition on bacterial surfaces after treatment.Composite image: 8 micrographs of cocci and rod bacteria, untreated vs copper aluminum hydroxide. Representative SEM images of (A) coccoid (upper panel) and (B) rod-shaped (lower panel) bacteria following LDH treatment. Untreated bacteria exhibited intact morphology with smooth cell surfaces, whereas LDH-treated bacteria showed surface roughening, deformation, shrinkage, and aggregation. High-magnification images (bottom row of each panel) highlight structural damage and nanoparticle deposition on bacterial surfaces after treatment. Anticancer Activities and Cytotoxicity of CuAl LDHs We then evaluated the anticancer potential of CuAl LDHs across different cell models. A concentration-dependent cytotoxic effect was observed in all tested cell lines. CuAl LDHs showed greater growth inhibition in HCT-116 cells (IC50 – 80.81 μg/mL) compared with HT-29 (IC50 – 224.74 μg/mL) in 2D monolayer cultures (Table 2). At 125 μg/mL, ~75% inhibition was observed in HCT-116 cells, while only ~25% inhibition was seen in HT-29 cells (Figure 5A). CuAl LDHs physically interacted with the cell surfaces without entering the intracellular compartments (Supplementary Figure 1). The dark particles corresponding to CuAl LDHs did not colocalize with DAPI-stained nuclei in the merged images. This effect was prominent in HT-29 cells treated with 250 μg/mL CuAl LDHs (near the IC50 concentration), where a dense accumulation of LDHs was observed surrounding the cells. As multiple PBS washing steps were performed during staining, only LDHs with strong electrostatic or surface interactions remained bound to the cells, while those with weaker interactions were washed away. We then performed ICP-MS analysis to quantify the intracellular accumulation of Cu and Al. As shown in Table 3, treatment with CuAl LDHs resulted in a pronounced increase in the intracellular levels of both Cu and Al in CRC cells compared with untreated controls. Notably, HT-29 cells exhibited higher intracellular Cu and Al accumulation than HCT-116 cells. However, this did not correlate with enhanced anticancer activity, as HT-29 cells displayed a higher IC50 value (Table 2), indicating lower sensitivity to CuAl LDH treatment. To assess the cytotoxicity of CuAl LDHs in normal cells, we tested them on NCM460 normal colon epithelial cells and HaCaT keratinocytes. At 125 μg/mL, CuAl LDHs caused 100% inhibition in NCM460 cells and 67% in HaCaT cells (Figure 5B). The IC50 values were 24.29 μg/mL for NCM460 and 101.46 μg/mL for HaCaT (Table 2), indicating some degree of toxicity to healthy cells.Table 2IC50 Values of CuAl LDHs in Colorectal Cancer (CRC) and Non-Cancer Cell LinesIC50 (µg/mL)Colorectal CancerNon-Cancer HCT-116 HT-29NCM460HaCaT2D Monolayer3D Spheroid2D Monolayer3D SpheroidCuAl LDH80.81 ± 3.0415.25 ± 1.94224.74 ± 30.3338.75 ± 1.8024.29 ± 3.47101.46 ± 2.0 Table 3Cellular Uptake of CuAl LDHs by ICP-MSElement/Cell (ng/million)CuAlHCT-116Untreated3.95 ± 0.05730.91 ± 0.36CuAl LDH664.9 ± 13.33458.99 ± 6.0HT-29Untreated3.63 ± 0.08212.71 ± 0.12CuAl LDH8606.88 ± 152.43898.71 ± 56.79 Figure 5Cytotoxicity of CuAl-LDHs (0–1000 μg/mL) in monolayer models (A) colorectal cancer cells; and (B) normal cells. Error bars represent SD. ns – not significant, *p < 0.05, **p < 0.01, ***p < 0.001.Image A shows a grouped bar graph of cell viability (%), ranging from 0 to 120. Categories: HCT 116 and HT 29. Doses: 0, 15.625, 31.25, 62.5, 125, 250, 500, 1000. HCT 116 bars: ~100, ~95 (ns), ~85 (**), ~70, ~25, ~2, ~0. HT 29 bars: ~100, ~95, ~100, ~90, ~75 (*), ~45, ~10, ~0. Brackets labeled ns and *** appear above groups. Image B shows a similar graph. Categories: NCM 460 and HaCaT. Doses: 0, 15.625, 31.25, 62.5, 125, 250, 500, 1000. NCM 460 bars: ~100, ~60 (**), ~50, ~8, ~0 for higher doses. HaCaT bars: ~100, ~110 (ns), ~110, ~85 (**), ~35, ~8, ~0 for higher doses. Brackets labeled ns and *** appear above groups.A grouped bar graph showing cell viability for HCT 116, H T 29, N C M 460 and HaCaT across doses. Table 2IC50 Values of CuAl LDHs in Colorectal Cancer (CRC) and Non-Cancer Cell LinesIC50 (µg/mL)Colorectal CancerNon-Cancer HCT-116 HT-29NCM460HaCaT2D Monolayer3D Spheroid2D Monolayer3D SpheroidCuAl LDH80.81 ± 3.0415.25 ± 1.94224.74 ± 30.3338.75 ± 1.8024.29 ± 3.47101.46 ± 2.0 IC50 Values of CuAl LDHs in Colorectal Cancer (CRC) and Non-Cancer Cell Lines Table 3Cellular Uptake of CuAl LDHs by ICP-MSElement/Cell (ng/million)CuAlHCT-116Untreated3.95 ± 0.05730.91 ± 0.36CuAl LDH664.9 ± 13.33458.99 ± 6.0HT-29Untreated3.63 ± 0.08212.71 ± 0.12CuAl LDH8606.88 ± 152.43898.71 ± 56.79 Cellular Uptake of CuAl LDHs by ICP-MS Cytotoxicity of CuAl-LDHs (0–1000 μg/mL) in monolayer models (A) colorectal cancer cells; and (B) normal cells. Error bars represent SD. ns – not significant, *p < 0.05, **p < 0.01, ***p < 0.001. Notably, CuAl LDHs effectively penetrated 3D tumor spheroids and demonstrated enhanced anticancer activity. The IC50 values in 3D models were significantly lower, at 15.25 μg/mL for HCT-116 and 38.75 μg/mL for HT-29 (Table 2), representing a 5-6-fold increase in potency compared to monolayer cultures. At 125 μg/mL, CuAl LDHs achieved up to 97% and 95% inhibition in HCT-116 and HT-29 3D spheroids, respectively (Figure 6A), highlighting their promising efficacy in more clinically relevant models. We then performed live/dead cell staining to assess the viability of spheroids following treatment (Figure 6B). Substantial accumulation of red fluorescent PI-stained dead cells was observed within the central core and among dispersed cells surrounding the spheroids. A reduction in spheroid size was also observed, indicating disintegration and shrinkage of the 3D tumor structure. In contrast, untreated spheroids exhibited minimal cell death, with green Calcein AM fluorescence marking predominantly viable cells at the periphery. Figure 6Cytotoxicity of CuAl-LDHs in colorectal cancer tumor spheroids through (A) luminescence-based cell viability assay, error bars represent SD, ***p < 0.001; and (B) live/ dead cell staining using Calcein AM and PI dyes following 24-hr treatment of respective IC50 concentrations, scale bars in the images represents 100 µm.Image A displays a bar chart of cell viability (%) for HCT-116 and HT-29 across CuAl LDH concentrations: 0, 15.625, 31.25, 62.5, 125, 250, 500, 1000. The Y-axis shows cell viability percentages from 0 to 120. For HCT-116, viability drops from ~100% at 0 to ~50% at 15.625, ~20% at 31.25, ~10% at 62.5 and near 0% from 125 onwards. For HT-29, viability decreases from ~100% at 0 to ~80% at 15.625, ~60% at 31.25, ~30% at 62.5, ~5% at 125 and near 0% from 250 onwards. Asterisks indicate significance over each cell line group. Image B shows a 4x4 microscopy grid of tumor spheroids with columns for HCT-116 and HT-29, each divided into Untreated and CuAl LDH. Rows are labeled Brightfield, PI, Calcein AM, Merged, with a 100 micrometer scale bar. Brightfield shows one spheroid per condition. PI shows sparse signal in untreated and stronger in CuAl LDH. Calcein AM shows a bright ring in untreated and reduced in CuAl LDH. Merged tiles combine PI and Calcein AM patterns.Two-part scientific figure: CuAl LDH lowers HCT-116 and HT-29 spheroid viability and increases PI staining. Cytotoxicity of CuAl-LDHs in colorectal cancer tumor spheroids through (A) luminescence-based cell viability assay, error bars represent SD, ***p < 0.001; and (B) live/ dead cell staining using Calcein AM and PI dyes following 24-hr treatment of respective IC50 concentrations, scale bars in the images represents 100 µm. Total ROS and Mitochondrial Superoxide Assays To evaluate the mechanistic action of the anticancer CuAl LDHs in CRC cells, we performed a ROS assay. As shown in Figure 7A, CuAl-LDH-treated CRC cells exhibited markedly stronger green fluorescence than the untreated controls, indicating a substantial increase in intracellular ROS levels. Quantitative analysis revealed that treatment with CuAl-LDH at the respective IC50 concentrations increased total ROS production by approximately six-fold in HCT-116 cells and 14-fold in HT-29 cells compared with the untreated controls (Figure 7B). Figure 7Reactive oxygen species (ROS) assay of HCT-116 and HT-29 treated with IC50 concentration of CuAl LDH. (A) Images show the ROS level by DCFH-DA fluorescence. Scale bar represents 200 μm; (B) The histograms quantify the DCFH-DA fluorescence in four representative images containing cells. Error bars represent SD. **p < 0.01, ***p < 0.001.Image A displays microscopy images of HCT-116 and HT-29 cells under Untreated and CuAl LDH conditions, organized in Brightfield, DCFH-DA and Merged rows. HCT-116 shows sparse DCFH-DA signals when Untreated and numerous bright signals with CuAl LDH; these are overlaid in the Merged row. HT-29 exhibits similar patterns with more signals in CuAl LDH. Image B presents bar charts for HCT-116 and HT-29, comparing DCFH-DA fluorescence between Untreated and CuAl LDH. The y-axis ranges from 0 to 20. In HCT-116, Untreated measures around 1, CuAl LDH about 6.5, with error bars and a significant difference marked by asterisks. HT-29 shows Untreated at approximately 1 and CuAl LDH at about 14, also with error bars and significant difference indicated by asterisks.Composite image: fluorescence micrographs and bar charts of DCFH-DA fluorescence in HCT-116, HT-29. Reactive oxygen species (ROS) assay of HCT-116 and HT-29 treated with IC50 concentration of CuAl LDH. (A) Images show the ROS level by DCFH-DA fluorescence. Scale bar represents 200 μm; (B) The histograms quantify the DCFH-DA fluorescence in four representative images containing cells. Error bars represent SD. **p < 0.01, ***p < 0.001. To determine whether the observed increase in intracellular ROS was associated with mitochondrial oxidative stress, mitochondrial superoxide production was subsequently assessed. As shown in Figure 8A, untreated HCT-116 and HT-29 cells exhibited only weak basal red fluorescence, reflecting low endogenous mitochondrial superoxide levels. In contrast, CuAl-LDH-treated cells displayed a marked increase in red fluorescence intensity, predominantly localized within the perinuclear region, indicating enhanced mitochondrial superoxide generation. Quantitative analysis further confirmed these observations (Figure 8B), demonstrating that CuAl-LDH treatment significantly elevated mitochondrial superoxide levels by approximately 12-fold in HCT-116 cells and 10-fold in HT-29 cells compared with the untreated controls. Collectively, these findings demonstrate that CuAl-LDH induces pronounced mitochondrial oxidative stress in CRC cells, suggesting that mitochondria are a major source of the excessive ROS generated following CuAl-LDH treatment. Figure 8Mitochondrial superoxide assay of HCT-116 and HT-29 treated with IC50 concentration of CuAl LDH. (A) Images show mitochondrial superoxide levels using MitoNeoD fluorescence. Scale bar represents 200 μm. (B) The histograms quantify the average MitoNeoD fluorescence per cell. Error bars represent SD. *p < 0.05.The image A showing two microscopy blocks labeled HCT-116 and HT-29, each arranged as three columns, untreated, CuAl-LDH and positive control and four rows, Hoechst 33342, MitoNeoD, merged and enlarged. Each merged row includes a small square marking the region shown in the enlarged row. Each microscopy tile includes a scale bar labeled 200 micrometer. The image B showing two bar charts labeled HCT-116 and HT-29. Each chart has x-axis labels, untreated and CuAl-LDH. Each chart has y-axis label, MitoNeoD fluorescence left parenthesis arbitrary unit right parenthesis, with tick labels 0, 5, 10, 15, 20. Each chart shows two bars with error bars. A bracket above the two bars is marked with asterisk. HCT-116 bar heights are approximately 1 for untreated and approximately 13 for CuAl-LDH. HT-29 bar heights are approximately 1 for untreated and approximately 10 for CuAl-LDH.Composite figure with microscopy and two bar charts for HCT-116 and HT-29, untreated vs CuAl-LDH. Mitochondrial superoxide assay of HCT-116 and HT-29 treated with IC50 concentration of CuAl LDH. (A) Images show mitochondrial superoxide levels using MitoNeoD fluorescence. Scale bar represents 200 μm. (B) The histograms quantify the average MitoNeoD fluorescence per cell. Error bars represent SD. *p < 0.05. Apoptosis Assay We then performed an Annexin V-FITC/PI assay to detect cell apoptosis. Figure 9A demonstrates that IC50 concentrations of CuAl LDHs resulted in early and/or late apoptosis in CRC cells. In HCT-116 cells, about 8% and 25% increases in early and late apoptosis, respectively was observed following CuAl LDH treatment. In HT-29 cells, about an 18% increase in early apoptosis was observed (Figure 9B). To investigate the molecular mechanisms underlying apoptotic induction, we performed gene expression analysis (Figure 9C). CuAl LDH treatment led to significant downregulation of the anti-apoptotic genes BCL-2 and BCL2L1, while the pro-apoptotic gene BAX was also found to be suppressed. The expression of another pro-apoptotic gene, CASP3, was not significantly altered in HT-29 cells. Figure 9Apoptosis assay of CRC cells treated with IC50 concentration of CuAl LDH. Cells were stained by PI and Annexin V-FITC. (A) Density plots show the HCT-116 (upper panel) and HT-29 (lower panel) in the live, early apoptosis, late apoptosis, and dead stages; (B) Histograms show the percentage of HCT-116 (left panel) and HT-29 (right panel) at various stages; (C) The histograms show the relative expression of BCL-2, BCL2L1, BAX, and CASP3 after CuAl treatment. Error bars represent SD. ns – not significant, *p < 0.05, **p < 0.01, ***p < 0.001.The image A shows density plots of HCT-116 and HT-29 cells untreated and treated with CuAl LDH, indicating live, early apoptosis, late apoptosis and dead stages. The image B shows histograms of HCT-116 and HT-29 cells, displaying the percentage of cells in live, early apoptosis, late apoptosis and dead stages for untreated and CuAl-LDH treated groups. The image C shows histograms of relative expression of genes BCL-2, BCL2L1, BAX and CASP3 in untreated, HCT-116 and HT-29 cells. Significant changes are marked with asterisks: p < 0.05, p < 0.01, p < 0.001 and ns for not significant.Density plots and histograms of CRC cells showing apoptosis stages and gene expression after CuAl LDH treatment. Apoptosis assay of CRC cells treated with IC50 concentration of CuAl LDH. Cells were stained by PI and Annexin V-FITC. (A) Density plots show the HCT-116 (upper panel) and HT-29 (lower panel) in the live, early apoptosis, late apoptosis, and dead stages; (B) Histograms show the percentage of HCT-116 (left panel) and HT-29 (right panel) at various stages; (C) The histograms show the relative expression of BCL-2, BCL2L1, BAX, and CASP3 after CuAl treatment. Error bars represent SD. ns – not significant, *p < 0.05, **p < 0.01, ***p < 0.001. Cell Cycle Analysis Figure 10A demonstrates that CuAl LDHs slightly induced cell cycle arrest in the S (DNA synthesis) phase (~2-5%) in both CRC cell lines compared to the untreated cells (Figure 10B). However, these differences were not statistically significant. In HT-29 cells, treatment with CuAl LDHs significantly reduced the G1 phase cell population (~5%), which may impact overall cell proliferation. Although an increase in S phase arrest was also observed, consistent with the trend seen in HCT-116 cells, this change was not statistically significant. As shown in Figure 10C, gene expression analysis indicated that key cell cycle regulators CCNE1, CCNB1, and CDK1 were affected by the treatment. However, the lack of significant changes in the cell cycle distribution suggests that additional regulatory mechanisms beyond classical cell cycle control may be involved in the response to CuAl LDHs. Figure 10Cell cycle analysis of HCT-116 and HT-29 treated with IC50 concentration of CuAl LDH. (A) The graph shows the DNA stains of HCT-116 (upper panel) and HT-29 (lower panel) by propidium iodide (PI) in G1, S, and G2/M phases; (B) The histograms show the percentage of HCT-116 (left panel) and HT-29 (right panel) in the G1, S, and G2/M phases following the CuAl LDH treatment; (C) The histograms show the relative expression of CCNE1, CCNB1, and CDK1 after CuAl treatment. Error bars represent SD. ns – not significant, *p < 0.05, **p < 0.01, ***p < 0.001.A series of graphs analyzing cell cycle phases and gene expression in HCT-116 and HT-29 cells. A) Histograms display DNA stains of HCT-116 (top) and HT-29 (bottom) cells, untreated and treated with CuAl LDH, showing G1, S and G2/M phases. B) Bar charts illustrate the percentage of cells in G1, S and G2/M phases for HCT-116 and HT-29, comparing untreated and CuAl LDH-treated groups. Statistical significance is indicated as ns (not significant), p < 0.05. C) Bar charts show relative expression of CCNE1, CCNB1 and CDK1 genes in untreated, HCT-116 and HT-29 cells, with significance marked as ns, p < 0.001, p < 0.01.Graphs show cell cycle phases and gene expression in HCT-116 and HT-29 cells treated with CuAl LDH. Cell cycle analysis of HCT-116 and HT-29 treated with IC50 concentration of CuAl LDH. (A) The graph shows the DNA stains of HCT-116 (upper panel) and HT-29 (lower panel) by propidium iodide (PI) in G1, S, and G2/M phases; (B) The histograms show the percentage of HCT-116 (left panel) and HT-29 (right panel) in the G1, S, and G2/M phases following the CuAl LDH treatment; (C) The histograms show the relative expression of CCNE1, CCNB1, and CDK1 after CuAl treatment. Error bars represent SD. ns – not significant, *p < 0.05, **p < 0.01, ***p < 0.001. Discussion The XRD pattern of CuAl LDHs corresponded to JCPDS No. 00–046-0099 and 01–085-7183 standard cards which are consistent with previous reports.9,22 According to the DLS measurements, the hydrodynamic diameter of the CuAl LDHs was approximately 600 nm. This particle size is comparable to that reported in our previous study, in which CuAl LDHs synthesized using a hydrothermal method exhibited a hydrodynamic diameter of approximately 568 nm.23 However, the particles obtained in the present study were larger than those reported for most CuAl LDHs in the literature. For example, Kiani et al reported CuAl LDHs with an average particle size of approximately 70 nm,8 whereas another study reported CuAl LDHs with particle sizes ranging from 220 to 350 nm.24 These differences are likely attributable to variations in synthesis methods, precursor compositions, reaction conditions, and post-synthesis processing, all of which can significantly influence particle nucleation, crystal growth, and aggregation behavior. In particular, factors such as metal ion concentration, pH, aging time, temperature, and hydrothermal treatment have been shown to affect the final particle size and morphology of LDHs. Notably, CuAl LDHs were slightly larger at pH 6.0 compared to pH 7.4. This may be attributed to the formation of a more stable hydration layer at neutral pH, resulting in better colloidal dispersion. In contrast, acidic pH may promote intercalation of protons or ions, causing slight swelling of the layers.25 Additionally, the lower surface charge at acidic pH (+36.7 mV) compared to that at pH 8 (+38.28 mV) may reduce electrostatic repulsion, resulting in mild particle aggregation, thereby contributing to the slightly larger hydrodynamic size.26 In general, the zeta potential values of the LDHs obtained in the present study were consistent with those reported in our previous work.23 The zeta potential of CuAl LDHs remained highly positive across acidic and neutral pH values but decreased sharply at pH 11. This phenomenon is consistent with the surface chemistry of LDHs under strongly alkaline conditions. At high pH, abundant OH− ions compete with surface hydroxyl groups, leading to deprotonation of the LDH surface and neutralization of positive surface charges. In addition, the increased ionic strength compresses the electrical double layer surrounding the particles, resulting in a lower measured zeta potential. Partial surface reconstruction or dissolution of the LDH layers under highly alkaline conditions may further contribute to the reduction in surface charge. Despite the decrease in zeta potential, the crystalline LDH structure remained largely intact within the physiologically relevant pH range (pH 5–8), indicating that the nanoparticles retain their colloidal stability under biological conditions. The EDS data showed the presence of Cu, O, C, Al, and N elements, which is consistent with previous publications.23,27 CuAl LDH was less effective against Gram-negative strains, with MIC50 values exceeding 1 mg/mL. This could be due to their outer membrane which acts as a barrier, along with the presence of possible efflux pumps that resist the CuAl-mediated bacterial killing.28 Gram-positive bacteria possess a thick but porous peptidoglycan layer that lacks an outer membrane, allowing positively charged CuAl LDHs and released Cu2⁺ ions to interact more readily with the cytoplasmic membrane. These interactions can disrupt membrane integrity, promote ROS generation, interfere with respiratory enzymes, and ultimately induce cell death. In contrast, Gram-negative bacteria possess an additional outer membrane enriched with negatively charged lipopolysaccharides, which acts as an effective permeability barrier against nanoparticles and metal ions. This outer membrane limits nanoparticle penetration and reduces intracellular accumulation of copper ions, thereby decreasing antibacterial efficacy. Furthermore, many Gram-negative bacteria express efficient metal efflux systems and oxidative stress response pathways that enhance their tolerance toward copper-induced toxicity. Consequently, higher concentrations of CuAl LDHs are required to inhibit Gram negative bacterial growth compared with Gram-positive species. Previously, CuAl LDHs synthesized via the co-precipitation method have demonstrated strong antibacterial effects against S. aureus, E. coli, and K. pneumoniae at 0.1–0.5 mg/mL.12 In another study, CuAl LDHs modified with plant extracts effectively killed B. cereus and P. aeruginosa at 5 mg/mL.8 Liu et al reported that 10–50 μg/mL cerium (Ce)-doped CuAl LDHs also exhibited potent antibacterial activity against S. aureus and E. coli.29 Similarly, Li et al constructed various LDHs, including CuAl LDH, which significantly inhibited the growth of S. aureus and E. coli at 0.8–1.5 mg/mL.13 As bacterial biofilms play a critical role in chronic infections by colonizing medical devices and body tissues,30 and significantly contribute to antimicrobial resistance,29 we further evaluated the antibiofilm activity of CuAl LDHs. Interestingly, more prominent biofilm inhibition was seen in Gram-negative bacteria compared with Gram-positive bacteria, which is contradictory to the antibacterial data. This disparity may be attributed to differences in biofilm matrix composition, such as polysaccharides and amyloid-type proteins, and their regulatory mechanisms across bacterial species.31 Biofilm formation in Gram-negative bacteria is tightly regulated by quorum sensing networks and extracellular polymeric substances (EPS). Positively charged CuAl LDHs can electrostatically interact with negatively charged EPS components, destabilizing the biofilm matrix and reducing its structural integrity. In addition, copper ions released from the LDHs may interfere with quorum sensing signaling pathways, suppress bacterial adhesion, and inhibit EPS biosynthesis during the early stages of biofilm formation. Gram-negative biofilms generally contain abundant extracellular polysaccharides, extracellular DNA, and proteins that provide multiple negatively charged binding sites for cationic nanoparticles. Consequently, CuAl LDHs may accumulate preferentially within the biofilm matrix, resulting in more efficient disruption of biofilm architecture than inhibition of planktonic bacterial growth. These findings suggest that CuAl LDHs may be particularly valuable for preventing biofilm-associated infections, where inhibition of biofilm establishment is often more clinically relevant than bactericidal activity alone. To the best of our knowledge, this is the first study to evaluate the antibacterial and antibiofilm effects of CuAl LDHs against S. gallolyticus, S. epidermidis, K. aerogenes, and P. vulgaris. Among the four tested bacteria, S. gallolyticus and K. aerogenes are highly associated with CRC pathogenesis,14,15 whereas S. epidermidis and P. vulgaris are commonly linked to human infections of the skin and urinary tract, respectively.32,33 Our findings suggest that larger CuAl LDH aggregates predominantly interact with the cell surface, whereas smaller CuAl LDHs are more efficiently internalized by CRC cells, leading to cancer cell death. From the cytotoxicity data, CuAl LDH also showed killing activity in normal colon epithelial cells and human skin keratinocytes. The target selectivity of CuAl LDHs can potentially be improved through surface modification strategies, which we plan to explore in future work. For example, galactose (Gal)-modified LDHs have shown enhanced cellular uptake and cytotoxicity in HepG2 liver cancer cells through targeting ASGPR receptors.34 Similarly, Mei et al demonstrated that folic acid (FA)-conjugated, doxorubicin (DOX)-loaded LDHs selectively targeted KB cells, a subline of HeLa cells, leading to improved anticancer activity.35 These findings suggest promising avenues for enhancing the specificity and therapeutic index of CuAl LDHs. This is the first study to investigate the anticancer activity of CuAl LDHs in CRC cells. Previous research has primarily focused on LDHs as nanocarriers to deliver chemotherapeutic agents or to explore combination therapies in CRC models. For instance, Chen et al reported that Mg2Al LDHs loaded with 5-FU, when combined with the PI3K/mTOR dual inhibitor BEZ-235, effectively inhibited HCT-116 cell growth.36 Li et al developed albumin-stabilized Mg2Al LDHs co-loaded with 5-FU and Abraxane (ABX), which significantly suppressed HCT-116 proliferation.37 Similarly, Pooresmaeil et al showed that Zn/Al LDHs loaded with 5-FU exerted strong anticancer effects in HT-29 cells,38 and Ranjbar et al demonstrated effective growth inhibition in Caco-2 CRC cells using Mg/Al LDHs loaded with 5-FU.39 In this study, we not only highlight the standalone anticancer potential of CuAl LDHs but also evaluate the cytotoxic effects of CuAl-5FU complexes in both 2D monolayer and 3D tumor spheroid models, alongside exploring the underlying mechanisms of action. Previous studies have reported that CuAl LDH can generate ROS and enhance antibacterial activity against various bacterial strains, including S. aureus, E. coli, and K. pneumoniae.12 In human cells, Mg/Al LDHs can induce ROS production in A549 lung cancer cells, leading to inhibited cell proliferation.40 In 4T1 and HepG2 cancer cells, CuAl LDH can consume the overexpressed glutathione (GSH) through redox reactions and generate toxic •OH to eliminate the cancer cells.41 To the best of our knowledge, this is the first study to report the ROS-inducing effects of CuAl LDH in CRC cells. ROS are known to activate apoptosis by regulating mitochondrial proteins.42 Therefore, the apoptotic activity seen in the CRC cells could be due to the ROS-inducing activity of CuAl LDH. Previous studies have shown that various LDHs could induce apoptosis in cancer cells. For instance, Busa et al constructed CuAl LDH and loaded them with DOX and polydopamine (PDA) for anticancer experiments in A549 lung cancer cells.43 The CuAl LDHs could kill the A549 cells by inducing ROS production and reducing the GSH levels.43 In another study, Pang et al generated Mg-Fe LDHs that could effectively kill breast cancer cells in vitro and in vivo by inducing ROS production, enhancing oxidative stress followed by ferroptosis and apoptosis.44 The marked increase in mitochondrial superoxide production also suggests that CuAl-LDH disrupts mitochondrial redox homeostasis in CRC cells. Mitochondrial superoxide is primarily generated through electron leakage from the mitochondrial electron transport chain, and its excessive accumulation is a hallmark of mitochondrial dysfunction. Elevated mitochondrial superoxide can promote oxidative damage to mitochondrial proteins, lipids, and DNA, ultimately leading to mitochondrial membrane depolarization and activation of apoptotic signaling pathways.45 These findings are consistent with our previous JC-1 assay results, which demonstrated a loss of mitochondrial membrane potential following CuAl-LDH treatment, supporting the notion that mitochondrial dysfunction is a key mechanism underlying CuAl-LDH-induced cytotoxicity.23 From the gene expression study, CuAl LDH treatment led to significant downregulation of the anti-apoptotic genes BCL-2 and BCL2L1, suggesting that LDHs may interfere with their role in preventing cytochrome c release from mitochondria.46 Interestingly, the pro-apoptotic gene BAX was also found to be suppressed, indicating a complex regulatory response that may involve both mitochondrial and non-mitochondrial apoptotic pathways.47 The expression of another pro-apoptotic gene, CASP3, was not significantly altered in HT-29 cells, which may explain the induction of early-stage apoptosis without progression to late-stage apoptosis. This limited activation of the apoptotic pathway is consistent with the known characteristics of HT-29 cells, which harbor a mutated TP53 gene. The dysfunctional p53 pathway in these cells contributes to their reduced sensitivity to apoptosis compared with TP53-wild-type HCT-116 cells. In contrast, CASP3 expression was decreased in HCT-116 cells, possibly due to feedback inhibition from upstream apoptotic signals, such as the paradoxical regulation of procaspase-3,48 or to cell line-specific resistance mechanisms affecting caspase activation.49 Although BAX, BCL-2, and CASP3 transcript levels were reduced following CuAl-LDH treatment, this does not exclude apoptosis. Apoptosis is primarily regulated through post-translational activation of BAX and proteolytic cleavage of caspase-3 rather than increased gene transcription. Furthermore, prolonged oxidative stress and advanced apoptotic progression can suppress global transcription, leading to decreased mRNA abundance despite ongoing apoptotic signaling. Considering that CuAl-LDH induces substantial ROS generation and mitochondrial dysfunction, apoptosis is likely mediated through mitochondrial activation and caspase cleavage, while concurrent cuproptotic signaling may also contribute to cell death, which requires further investigation. It is well known that cell cycle regulators can influence cell proliferation and apoptosis,50 hence, we evaluated the effect of CuAl LDHs on the cell cycle of CRC cells. As CuAl LDHs induced ROS production, oxidative stress may alter transcription factors such as p53, NF-κB, or E2F, which regulate the expression of CCNE1, CCNB1, and CDK1.51 For instance, elevated ROS or DNA damage can activate p53, which suppresses CCNE1 and CDK1 expression through p21 upregulation, even without clear G1/S or G2/M arrest.52 These changes could contribute to the downregulation of these cell cycle genes through a mechanism independent of classical cell cycle arrest. Conclusion In this study, we demonstrate that CuAl LDHs exhibit bacteriostatic activity, particularly against Gram-positive bacteria, while showing strong antibiofilm activity in Gram-negative strains. In anticancer evaluations, CuAl LDHs displayed significant cytotoxic effects against CRC cells in both monolayer and 3D spheroid models. Mechanistic analyses indicated that these effects are primarily driven by ROS production, mitochondrial superoxide generation, and apoptosis induction. Although moderate cytotoxic effects were also observed in normal cells, strategies such as targeted drug delivery and surface functionalization may improve tumor selectivity and biocompatibility. Future work should also focus on reducing particle size, minimizing aggregation, and optimizing surface properties to enhance cellular uptake, tumor penetration, biodistribution, and suitability for systemic administration. Overall, these findings provide proof of concept that CuAl LDHs possess promising antibacterial and anticancer activities in vitro and establish a foundation for further optimization and comprehensive in vivo evaluation before their therapeutic potential can be fully assessed.